CL2016001357A1 - Agonistas de a1 de adenosina como medicamentos para trastornos renales - Google Patents

Agonistas de a1 de adenosina como medicamentos para trastornos renales

Info

Publication number
CL2016001357A1
CL2016001357A1 CL2016001357A CL2016001357A CL2016001357A1 CL 2016001357 A1 CL2016001357 A1 CL 2016001357A1 CL 2016001357 A CL2016001357 A CL 2016001357A CL 2016001357 A CL2016001357 A CL 2016001357A CL 2016001357 A1 CL2016001357 A1 CL 2016001357A1
Authority
CL
Chile
Prior art keywords
adenosine
agonists
medicines
kidney disorders
disorders
Prior art date
Application number
CL2016001357A
Other languages
English (en)
Inventor
Alexandros Vakalopoulos
Barbara Albrecht-Küpper
Kirsten Leineweber
Axel Kretschmer
Daniel Meibom
Nicole Diedrichs
Katja Zimmermann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49759125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001357(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2016001357A1 publication Critical patent/CL2016001357A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS AGONISTAS DEL RECEPTOR A1 DE ADENOSINA PARA TRATAR Y/O PREVENIR TRASTORNOS RENALES AGUDOS Y/O CRÓNICOS.
CL2016001357A 2013-12-12 2016-06-03 Agonistas de a1 de adenosina como medicamentos para trastornos renales CL2016001357A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13196780 2013-12-12

Publications (1)

Publication Number Publication Date
CL2016001357A1 true CL2016001357A1 (es) 2017-01-13

Family

ID=49759125

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001357A CL2016001357A1 (es) 2013-12-12 2016-06-03 Agonistas de a1 de adenosina como medicamentos para trastornos renales

Country Status (21)

Country Link
US (1) US20160311812A1 (es)
EP (1) EP3079696A1 (es)
JP (1) JP2016539986A (es)
KR (1) KR20160094974A (es)
CN (1) CN105792826A (es)
AP (1) AP2016009245A0 (es)
AU (1) AU2014363705A1 (es)
CA (1) CA2933244A1 (es)
CL (1) CL2016001357A1 (es)
EA (1) EA201691218A1 (es)
IL (1) IL245866A0 (es)
MA (1) MA39101A1 (es)
MX (1) MX2016007343A (es)
MY (1) MY174230A (es)
PH (1) PH12016501127A1 (es)
SG (1) SG11201604414PA (es)
SV (1) SV2016005210A (es)
TN (1) TN2016000233A1 (es)
UA (1) UA117771C2 (es)
WO (1) WO2015086561A1 (es)
ZA (1) ZA201603465B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7055429B2 (ja) * 2017-10-27 2022-04-18 学校法人北里研究所 慢性腎臓病の予防又は治療剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007036075A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Ag Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

Also Published As

Publication number Publication date
SV2016005210A (es) 2017-08-08
CN105792826A (zh) 2016-07-20
IL245866A0 (en) 2016-07-31
UA117771C2 (uk) 2018-09-25
KR20160094974A (ko) 2016-08-10
ZA201603465B (en) 2019-07-31
JP2016539986A (ja) 2016-12-22
MX2016007343A (es) 2016-09-13
SG11201604414PA (en) 2016-07-28
AU2014363705A1 (en) 2016-06-30
MA39101A1 (fr) 2017-08-31
US20160311812A1 (en) 2016-10-27
AP2016009245A0 (en) 2016-05-31
EA201691218A1 (ru) 2016-11-30
TN2016000233A1 (en) 2017-10-06
WO2015086561A1 (de) 2015-06-18
EP3079696A1 (de) 2016-10-19
PH12016501127A1 (en) 2016-07-18
MY174230A (en) 2020-04-01
CA2933244A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
CL2015003089A1 (es) Heterociclos biciclicos como inhibidores de fgfr.
DK3368060T3 (da) Glugacon-receptor-agonister
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
DK3030581T3 (da) Antistofbindingssteder, der er specifikke for egfrviii
ES1121155Y (es) Dispositivo y herramientas para la osteosintesis del esternon.
CR20160136A (es) Compuestos heterocíclicos
BR112015025408A2 (pt) combinações de droga para tratar câncer
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
DE112014001481T8 (de) System für dynamisch einstellbare Arretierung
BR112017002318A2 (pt) combinações de fármacos para tratar mieloma múltiplo.
DK2968352T3 (da) Derivatiserede 3-styryl-cephalosporiner
BR112015019998A2 (pt) cartucho para utilização em dispositivos de purificação de água
BR112015032344A2 (pt) compostos isotiazolinas naftil- ou isoquinolinil-substituídos
CL2015003792A1 (es) Oligosacáridos sintéticos para vacuna de p. aeruginosa
CL2016001357A1 (es) Agonistas de a1 de adenosina como medicamentos para trastornos renales
BR112015027741A2 (pt) cache coerente de sistema com capacidade para dispersar/reunir
ES1079003Y (es) Proyectil para aerosiembra selectiva.
IL243730A0 (en) Vasopressin-2 receptor agonists
DK3074384T3 (da) Amidderivater til gpr119-agonist
CO7071130A2 (es) Nuevas combinaciones para tratar la leucemia mieloide aguda o la leucemia mieloide cronica
FR3031264B1 (fr) Systeme de distribution de contenus multimedias
GB201312010D0 (en) Receptor Agonists
FR3001837B1 (fr) Piece de support de cable, notamment pour aeronef.
ES1078453Y (es) Mecanismo de union para dos elementos de mueble